Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis
Abstract Background Several studies showed higher risks of cardiovascular complications to have been observed in patients with type 2 diabetes mellitus (T2DM). Atrial fibrillation (AF) and atrial flutter have been more pronounced in patients with hyperglycemia. Sodium-glucose co-transporter 2 (SGLT2...
Saved in:
Main Authors: | Xiaoyan Liang, Jianghong Dai, Feifei Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | BMC Cardiovascular Disorders |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12872-024-04442-5 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01) -
The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors)
by: Denda Nikola I., et al.
Published: (2024-01-01) -
Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus
by: Soumitra Ray, et al.
Published: (2024-04-01) -
The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature
by: Silvia Ciraolo, et al.
Published: (2025-02-01) -
The protective role of SGLT2 inhibitors on aortic aneurysm mediated by oxidative stress and inflammation in type 2 diabetes mellitus
by: Rujie Zheng, et al.
Published: (2025-02-01)